These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 26317188)

  • 1. Sequential subtrochanteric femoral fracture after atypical diaphyseal fracture in a long-term bisphosphonate user: a case report.
    Park KT; Lee KB
    Acta Chir Orthop Traumatol Cech; 2015; 82(2):157-60. PubMed ID: 26317188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of bisphosphonate-associated femoral fractures.
    Shkolnikova J; Flynn J; Choong P
    ANZ J Surg; 2013 Mar; 83(3):175-81. PubMed ID: 23216704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.
    Capeci CM; Tejwani NC
    J Bone Joint Surg Am; 2009 Nov; 91(11):2556-61. PubMed ID: 19884427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of femoral fracture nonunion after long-term bisphosphonate use.
    Grady MK; Watson JT; Cannada LK
    Orthopedics; 2012 Jun; 35(6):e991-5. PubMed ID: 22691683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population.
    Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS
    Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Formation Parameters of the Biopsied Ilium Differ between Subtrochanteric and Diaphyseal Atypical Femoral Fractures in Bisphosphonate-Treated Patients.
    Kondo N; Fukuhara T; Watanabe Y; Miyasaka D; Yamamoto N; Sato H; Wada Y; Nakatsue T; Fujisawa J; Sakuma M; Imai N; Yoda T; Narita I; Endo N
    Tohoku J Exp Med; 2017 Dec; 243(4):247-254. PubMed ID: 29212985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical forearm fractures associated with long-term use of bisphosphonate.
    Moon J; Bither N; Lee T
    Arch Orthop Trauma Surg; 2013 Jul; 133(7):889-92. PubMed ID: 23619919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.
    Sasaki S; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
    J Bone Miner Metab; 2012 Sep; 30(5):561-7. PubMed ID: 22610061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral atypical femur fractures without bisphosphonate exposure.
    Szolomayer LK; Ibe IK; Lindskog DM
    Skeletal Radiol; 2017 Feb; 46(2):241-247. PubMed ID: 27900455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report.
    Bissonnette L; April PM; Dumais R; Boire G; Roux S
    Bone; 2013 Oct; 56(2):406-9. PubMed ID: 23871749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
    Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
    J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK; Tam KL; Krishnan SP; Maddern IL
    N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
    Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
    J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous Bilateral Femoral Fractures After High-Dose Zoledronic Acid.
    Brin YS; Palmanovich E; Heler Z; Kish BJ; Nyska M; Bismuth H; Coughlin R; Zehavi T; Rotman P
    Orthopedics; 2015 Nov; 38(11):e1051-4. PubMed ID: 26558671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.
    Patel VC; Lazzarini AM
    Orthopedics; 2010 Oct; 33(10):775. PubMed ID: 20954650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
    Cross MB; Nam D; van der Meulen MC; Bostrom MP
    J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
    Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
    Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
    Lenart BA; Neviaser AS; Lyman S; Chang CC; Edobor-Osula F; Steele B; van der Meulen MC; Lorich DG; Lane JM
    Osteoporos Int; 2009 Aug; 20(8):1353-62. PubMed ID: 19066707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-associated atypical subtrochanteric femur fracture.
    Wolin EA; Banks KP; Vroman PJ
    J Nucl Med Technol; 2015 Mar; 43(1):72-3. PubMed ID: 25125450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical bilateral femoral shaft fracture in patient treated with bisphosphonates.
    Parrón Cambero R; Rey López A; Tomé-Bermejo F; Cibantos Martínez R
    Eur J Orthop Surg Traumatol; 2013 Nov; 23 Suppl 2():S219-23. PubMed ID: 23412218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.